162 related articles for article (PubMed ID: 37763683)
1. Clinical Outcomes of Patients with Chronic Myeloid Leukemia and COVID-19 Infection-A Single Center Survey.
Ćojbašić I; Golubović I; Ćojbašić Ž
Medicina (Kaunas); 2023 Aug; 59(9):. PubMed ID: 37763683
[No Abstract] [Full Text] [Related]
2. [Response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia].
Ibarra-Hernández A; Sosa-Quintero LS; Garcés-Ruiz OM; Aguilar-López LB; Rubio-Jurado B; Vega-Ruiz A
Rev Med Inst Mex Seguro Soc; 2014; 52(3):266-9. PubMed ID: 24878084
[TBL] [Abstract][Full Text] [Related]
3. Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
Milojkovic D; Nicholson E; Apperley JF; Holyoake TL; Shepherd P; Drummond MW; Szydlo R; Bua M; Foroni L; Reid A; Khorashad JS; de Lavallade H; Rezvani K; Paliompeis C; Goldman JM; Marin D
Haematologica; 2010 Feb; 95(2):224-31. PubMed ID: 19833633
[TBL] [Abstract][Full Text] [Related]
4. Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors--a single center experience.
Ribeiro BF; Miranda EC; Albuquerque DM; Delamain MT; Oliveira-Duarte G; Almeida MH; Vergílio B; Silveira RA; Oliveira-Duarte V; Lorand-Metze I; De Souza CA; Pagnano KB
Clinics (Sao Paulo); 2015 Aug; 70(8):550-5. PubMed ID: 26247667
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
6. [Imatinib therapy in chronic myeloid leukemia].
Egyed M; Kollár B; Rajnics P; Karádi E; Matolcsi A
Orv Hetil; 2008 Aug; 149(32):1509-12. PubMed ID: 18672441
[TBL] [Abstract][Full Text] [Related]
7. Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment.
Iacobucci I; Rosti G; Amabile M; Poerio A; Soverini S; Cilloni D; Testoni N; Abruzzese E; Montefusco E; Ottaviani E; Iuliano F; Russo D; Gobbi M; Alimena G; Martino B; Terragna C; Pane F; Saglio G; Baccarani M; Martinelli G
J Clin Oncol; 2006 Jan; 24(3):454-9. PubMed ID: 16421422
[TBL] [Abstract][Full Text] [Related]
8. Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.
Kim TD; Türkmen S; Schwarz M; Koca G; Nogai H; Bommer C; Dörken B; Daniel P; le Coutre P
Haematologica; 2010 Apr; 95(4):582-8. PubMed ID: 20015884
[TBL] [Abstract][Full Text] [Related]
9. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
Yilmaz M; Lahoti A; O'Brien S; Nogueras-González GM; Burger J; Ferrajoli A; Borthakur G; Ravandi F; Pierce S; Jabbour E; Kantarjian H; Cortes JE
Cancer; 2015 Nov; 121(21):3894-904. PubMed ID: 26217876
[TBL] [Abstract][Full Text] [Related]
10. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F;
Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665
[TBL] [Abstract][Full Text] [Related]
11. [Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France Intergroupe des Leucémies Myéloïdes Chroniques].
Rea D; Ame S; Charbonnier A; Coiteux V; Cony-Makhoul P; Escoffre-Barbe M; Etienne G; Gardembas M; Guerci-Bresler A; Legros L; Nicolini F; Tulliez M; Hermet E; Huguet F; Johnson-Ansah H; Lapusan S; Quittet P; Rousselot P; Mahon FX; Messas E
Bull Cancer; 2016 Feb; 103(2):180-9. PubMed ID: 26790711
[TBL] [Abstract][Full Text] [Related]
12. Clinical characteristics and therapeutic outcomes of elderly patients with chronic myeloid leukemia: A retrospective multicenter study.
Korkmaz S; Dal MS; Berber I; Sahin DG; Dogu MH; Ayyildiz O; Nizam I; Albayrak M; Esen R; Namdaroglu S; Sencan M; Akay OM; Hacioglu S; Yildirim R; Eser A; Tombak A; Pala C; Ilhan O
Geriatr Gerontol Int; 2015 Jun; 15(6):729-35. PubMed ID: 25257190
[TBL] [Abstract][Full Text] [Related]
13. The Effectiveness of Tyrosine Kinase Inhibitors and Molecular Monitoring Patterns in Newly Diagnosed Patients With Chronic Myeloid Leukemia in the Community Setting.
Di Bella NJ; Bhowmik D; Bhor M; Yap M; Middlebrook B; Rembert D; Cain Z; Okoro T; Bolinder B; Patt D; Jabbour EJ
Clin Lymphoma Myeloma Leuk; 2015 Oct; 15(10):599-605. PubMed ID: 26208445
[TBL] [Abstract][Full Text] [Related]
14. Hematological and molecular response evaluation of CML patients on imatinib.
Gupta A; Prasad K
J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
16. The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study.
Di Felice E; Roncaglia F; Venturelli F; Mangone L; Luminari S; Cirilli C; Carrozzi G; Giorgi Rossi P
BMC Cancer; 2018 Nov; 18(1):1069. PubMed ID: 30400842
[TBL] [Abstract][Full Text] [Related]
17. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
[TBL] [Abstract][Full Text] [Related]
18. [Factors associated with achievement and durability of cytogenetic response in patients with chronic myeloid leukemia treated with imatinib].
Cojbasić I; Macukanović-Golubović L
Vojnosanit Pregl; 2011 Nov; 68(11):911-6. PubMed ID: 22191306
[TBL] [Abstract][Full Text] [Related]
19. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
Irvine E; Williams C
Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
[TBL] [Abstract][Full Text] [Related]
20. Molecular monitoring of imatinib in chronic myeloid leukemia patients in complete cytogenetic remission: does achievement of a stable major molecular response at any time point identify a privileged group of patients? A multicenter experience in Argentina and Uruguay.
Pavlovsky C; Giere I; Moiraghi B; Pavlovsky MA; Aranguren PN; García J; Fernandez I; Bengió R; Milone J; Labanca V; Uriarte R; Lombardi V; Reinoso FG; Magariños AE; Martinez L; Murro H; Lastiri F; Pavlovsky S
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):280-5. PubMed ID: 21658656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
